Estonie - estonien - Ravimiamet

mundipharma ges.m.b.h. - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 2,5mg+1,25mg 10tk; 2,5mg+1,25mg 56tk; 2,5mg+1,25mg 30tk; 2,5mg+1,25mg 98tk; 2,5mg+1,25mg 14tk; 2,5mg+1,25mg 100tk; 2,5mg+1,25mg 20tk; 2,5mg+1,25mg 60tk

Estonie - estonien - Ravimiamet

mundipharma ges.m.b.h. - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 30mg+15mg 60tk; 30mg+15mg 10tk; 30mg+15mg 100tk; 30mg+15mg 50tk; 30mg+15mg 98tk; 30mg+15mg 30tk

Estonie - estonien - Ravimiamet

mundipharma gesellschaft m.b.h. - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 40mg+20mg 98tk; 40mg+20mg 56tk; 40mg+20mg 100tk; 40mg+20mg 50tk; 40mg+20mg 30tk; 40mg+20mg 14tk; 40mg+20mg 10tk; 40mg+20mg 20tk

Estonie - estonien - Ravimiamet

mundipharma ges.m.b.h. - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 15mg+7,5mg 30tk; 15mg+7,5mg 20tk; 15mg+7,5mg 14tk; 15mg+7,5mg 60tk; 15mg+7,5mg 28tk

Estonie - estonien - Ravimiamet

mundipharma gesellschaft m.b.h. - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 5mg+2,5mg 100tk; 5mg+2,5mg 50tk; 5mg+2,5mg 30tk; 5mg+2,5mg 98tk; 5mg+2,5mg 28tk

Estonie - estonien - Ravimiamet

mundipharma gesellschaft m.b.h. - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 20mg+10mg 10tk; 20mg+10mg 50tk; 20mg+10mg 100tk; 20mg+10mg 56tk; 20mg+10mg 14tk; 20mg+10mg 30tk; 20mg+10mg 98tk; 20mg+10mg 20tk

Estonie - estonien - Ravimiamet

mundipharma ges.m.b.h. - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 80mg+40mg 28tk; 80mg+40mg 14tk; 80mg+40mg 60tk; 80mg+40mg 30tk; 80mg+40mg 56tk; 80mg+40mg 98tk

Estonie - estonien - Ravimiamet

mundipharma gesellschaft m.b.h. - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 10mg+5mg 28tk; 10mg+5mg 20tk; 10mg+5mg 98tk; 10mg+5mg 30tk; 10mg+5mg 60tk; 10mg+5mg 100tk; 10mg+5mg 14tk

Estonie - estonien - Ravimiamet

mundipharma ges.m.b.h. - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 60mg+30mg 28tk; 60mg+30mg 56tk; 60mg+30mg 14tk; 60mg+30mg 100tk; 60mg+30mg 60tk; 60mg+30mg 30tk

Union européenne - estonien - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastilised ained - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).